Precirix strengthens patent portfolio of its precision radiopharmaceuticals platform
Brussels, Belgium, 31 May 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today provides an update on its patent portfolio that has been strengthened with newly granted patents for its lead product candidate and expanded with filings for two novel compounds.
Precirix’ lead compound, CAM-H2, is protected by two broad patent families for which patents have been granted or a notice of allowance has been received, protecting both therapeutic as well as theragnostic claims in all key territories, including the US, Europe, Japan and China. Precirix is currently enrolling patients in the dose escalation portion of the Phase I/II trial of CAM-H2 for the treatment of patients with HER2-positive metastatic breast and gastric cancer. Importantly, the study includes patients with brain metastases, a significant unmet medical need affecting up to 50% of patients with HER2-positive metastatic breast cancer.
Additionally, the company filed patent applications for two novel single domain antibodies (sdAbs) targeting fibroblast activation protein (FAP), CAM-FAP, and folate receptor alpha (FRα), CAM-FR. These sdAbs exhibit excellent binding properties. Preclinical in vitro and in vivo studies have demonstrated their potential in diagnostic and therapeutic applications in combination with various isotopes.
CAM-FAP will be Precirix’ second pipeline candidate to enter the clinic. FAP is overexpressed in a range of tumor types, primarily on cancer-associated fibroblasts in the tumor microenvironment, while expression in normal adult tissues is absent or low, making it an ideal radiopharmaceutical target for pan-cancer development. The company plans to present preclinical data for CAM-FAP at upcoming scientific conferences.
Precirix is a private, clinical-stage biopharmaceutical company founded in 2014 as a spin-off from the VUB, dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labelled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a therapeutic dose for treatment. Precirix received grant funding from Innoviris Brussels to support this research.